|An alternatively spliced c-mil/raf mRNA is predominantly expressed in chicken muscular tissues and conserved among vertebrate species.
|Structure and biological activity of human homologs of the raf/mil oncogene.
|The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene.
|Phosphorylation of Raf by ceramide-activated protein kinase.
|Solution structure of the Ras-binding domain of c-Raf-1 and identification of its Ras interaction surface.
|The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue.
|Identification of the major phosphorylation sites of the Raf-1 kinase.
|The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site.
|Ras/Rap effector specificity determined by charge reversal.
|14-3-3 is phosphorylated by casein kinase I on residue 233. Phosphorylation at this site in vivo regulates Raf/14-3-3 interaction.
|The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338.
|Phosphorylation and regulation of Raf by Akt (protein kinase B).
|Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation.
|Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism.
|Positive and negative regulation of Raf kinase activity and function by phosphorylation.
|Phosphorylation of the myosin-binding subunit of myosin phosphatase by Raf-1 and inhibition of phosphatase activity.
|Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1.
|Dephosphorylation of Ser-259 regulates Raf-1 membrane association.
|The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins.
|Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1.
|Complete sequencing and characterization of 21,243 full-length human cDNAs.
|LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway.
|Raf kinase activation of adenylyl cyclases: isoform-selective regulation.
|The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
|Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.
|p21-activated Kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association.
|Raf-1 is a binding partner of DSCR1.
|Second nature: biological functions of the Raf-1 'kinase'.
|Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding.
|Regulation and role of Raf-1/B-Raf heterodimerization.
|A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.
|Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5.
|Raf 1 represses expression of the tight junction protein occludin via activation of the zinc-finger transcription factor slug.
|Phosphatase and feedback regulation of Raf-1 signaling.
|Patterns of somatic mutation in human cancer genomes.
|ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
|Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
|Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy.
|Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis.
|The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK.
|p21 activated kinase 5 activates Raf-1 and targets it to mitochondria.
|A quantitative atlas of mitotic phosphorylation.
|Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
|Retinoic acid induces nuclear accumulation of Raf1 during differentiation of HL-60 cells.
|Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions.
|Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization.
|Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis.
|RAF protein-serine/threonine kinases: structure and regulation.
|Noonan syndrome associated with both a new Jnk-activating familial SOS1 and a de novo RAF1 mutations.
|Initial characterization of the human central proteome.
|System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation.
|Raf family kinases: old dogs have learned new tricks.
|Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF.
|FAM83B mediates EGFR- and RAS-driven oncogenic transformation.
|Toward a comprehensive characterization of a human cancer cell phosphoproteome.
|Phosphodiesterase-8A binds to and regulates Raf-1 kinase.
|An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
|RAF1 mutations in childhood-onset dilated cardiomyopathy.